Marriott Marquis San Diego
Decemeber 15 - 18, 2024 Booth #301
GenScript is thrilled to announce our participation in the upcoming Antibody Engineering & Therapeutics 2024, which will be held at Marriott Marquis San Diego, from Decemeber 15th to 18th, 2024.
AET 2024 is the premier conference for antibody engineering, dedicated to accelerating the path to commercial success for next-generation antibodies. Over four engaging days, attendees will participate in workshops and presentations, gaining access to cutting-edge scientific research and insights on antibody engineering, design, and selection. The agenda features pivotal topics such as Antibody Therapy, Bi-Specifics, Antibody Fragments, VHH, and many other essential subjects crucial to the industry's advancement. Join us to shape the future of antibody innovation!
Come visit us at Booth #301!
Presentations and Posters
Presentation
Scientific Luncheon Briefing - Accelerating Antibody Drug discovery with GenScript’s MonoRab™ & TurboCHO™ platforms
Bio: Hui Foon Tan is a Global Product Manager who currently supports GenScript antibody discovery & production service. She graduated with her Ph.D. in Biological Sciences from Nanyang Technological University, Singapore, and continued to work as a Postdoctoral Research Fellow in cancer research for another two years. After she joined GenScript, Dr. Tan supported proteins and antibody production services in the APAC region for a year. She provides application support for pre- and post-sale activities for services, updates, and seminars to support co-stakeholders, distributors, and customers. Currently, she is supporting the launch of new services and training in antibody production services. She also collates market dynamics and competitive market information from the field to understand global market trends and collaborate with the team.
Abstract: The therapeutic antibody market is rapidly growing due to unmet needs and increased awareness of targeted therapies. The availability of advanced techniques and platforms in the market speeds up the process of antibody drug discovery to meet the increasing demands. GenScript's MonoRab™ and TurboCHO™ platforms streamline development, reducing timelines and costs. This integrated approach delivers high-quality therapeutic antibodies faster, addressing urgent medical needs and advancing biopharmaceutical innovation.
Scientific Luncheon Briefing - The development of a novel CD8-targeting lipid nanoparticle to transiently engineer CD8+ T cells in vivo using mRNA to express a CD19 CAR
Bio: Dr. Stuart Sievers is the Senior Director of Discovery Research at Capstan Therapeutics. His team focuses on antibody and chimeric antigen receptor (CAR) discovery and engineering, supporting the development of targeted lipid nanoparticles to engineer cells in vivo. Previously, Stuart worked at Kite Pharma, directing antibody discovery and CAR screening efforts to support the development of clinical- and commercial-stage cell therapies. Stuart earned his undergraduate degree in Biochemistry from UC Berkeley, his PhD in Biochemistry from UCLA under David Eisenberg, and completed postdoctoral research at Caltech with Pamela Bjorkman. His research has led to publications and patents on a variety of topics, including amyloid fibril formation and inhibition, antibody and CAR design, and novel reagents for CAR detection.
Abstract: Despite the success of ex vivo chimeric antigen receptor (CAR) T cell therapies, challenges in cell manufacturing, scalability, and the need for lymphodepleting chemotherapy highlight the necessity for an off-the-shelf in vivo CAR technology applicable to broader indications. To that aim, we developed CPTX2309, a novel in vivo anti-CD19 CAR mRNA product delivered by a CD8-targeted lipid nanoparticle (tLNP), optimized for pre-clinical performance and advancement to clinical development.
Scientific Briefing - Unlock a New Era of Automated Mini- and Maxi-Scale Plasmid Purification with AmMag™ Quatro Solutions
Bio: Dr. Luciana K. Rosselli-Murai is a highly skilled research scientist with over 7 years of experience in cell biology, cancer research, and cell signaling pathways. As the Head of the Field Application Scientist team for GenScript’s Products and Instruments Division, she oversees scientific operations across the USA and Europe. Dr. Rosselli-Murai holds a PhD in Genetics and Molecular Biology from Universidade Estadual de Campinas and completed her postdoctoral research at the University of Michigan. She specializes in GPCR research, protein biochemistry, and advanced imaging techniques, with a strong passion for driving innovation in Life Sciences and biological research.
Abstract: GenScript’s new AmMag™ Quatro Mini-1100 and Maxi-1400 systems, utilizing novel magnetic bead technology, provide automated, high-quality plasmid DNA purification. These advanced systems enhance throughput, yield, and reproducibility, handling culture volumes of up to 10 mL with the Mini-1100 and up to 200 mL with the Maxi-1400. Discover how these innovative solutions streamline workflows, delivering superior transfection-ready plasmid DNA and boosting lab efficiency and scalability.
Posters
Amanda Grimm
Sr. Segment Marketing Manager, GenScript USA Inc
Poster title: Decreasing the Complexity of Bispecific Antibody Discovery Description: Bispecific antibody drug development is a complex process requiring careful consideration of target biology, mechanism of action, antibody format, and other critical factors. Leveraging advanced technologies and strategic planning helps navigate these challenges and lead to successful therapeutic outcomes. Learn how GenScript’s integrated technologies support bispecific design, expression and assess developability.
Huifoon Tan, PhD
Sr. Global Product Manager, Product Marketing Department, GenScript
Poster title: Make Therapeutic Antibodies Fast via MonoRab™ & TurboCHO™ from GenScript Description: Therapeutic antibodies are the predominant class of drugs developed recently. With GenScript’s solutions, we aim to support antibody drug discovery and development via a simple yet specialized process, combining speed with quality towards IND. To overcome timeline challenge, we would highlight two major platforms: MonoRab™ (antibody discovery in 11 weeks & anti-Idiotype antibody discovery in 9 weeks) and TurboCHO™ (antibody production in 5 business days).
Rouba Najjar
Head of MKT and BD, Product Divisions, GenScript USA Inc
Poster title: Transforming High-Throughput Plasmid Purification with Automated Maxi-Scale AmMag™ Quatro Description: GenScript developed the AmMag™ Quatro, an innovative solution designed to automate the purification of large-scale, high-quality, transfection-grade plasmids. This modular system incorporates a central controller capable of simultaneously operating up to four independent purification modules. With pre-filled consumables and validated protocols, researchers can seamlessly process up to 6 samples per module, greatly enhancing throughput and efficiency. Leveraging magnetic bead technology and associated reagents, the AmMag Quatro streamlines the entire maxi-scale purification process, offering a dependable and efficient means of obtaining high-quality, transfection-grade pDNA samples. By reducing the potential for errors and enhancing reproducibility, this system represents a significant advancement in plasmid purification technology.
Most Popular Products
CRISPR Gene Editing
Antibodies
Protein Electrophoresis and Blotting
Molecular Biology
Stable Cell Lines
Cell Therapy
Diagnostics
Resources
Amanda Grimm
Huifoon Tan, PhD
Rouba Najjar
